Pomerantz probes ARS after neffy coverage update sends shares down 23.91%

The law firm said it is investigating whether ARS Pharmaceuticals and certain officers or directors engaged in securities fraud after the company disclosed neffy failed to secure commercial insurance coverage.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.